Torrent Pharmaceuticals Limited
TORNTPHARM
주식 순위
#1201
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
주가
$50.31
마지막 동기화: 2026-10-19
시가총액
$19.14B
변동 (1일)
-0.14%
변동 (1년)
23.83%
국가
IN
거래 Torrent Pharmaceuticals Limited (TORNTPHARM)
카테고리
Healthcare
Torrent Pharmaceuticals Limited (TORNTPHARM)의 수익
Jun 2026 기준 수익 TTM: $316.40M
Torrent Pharmaceuticals Limited의 최신 재무 보고서에 따르면 회사의 현재 수익은 $316.40M입니다. 2024년에 회사는 $282.08M의 수익을 올렸으며 이는 2023년의 수익 $224.77M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Torrent Pharmaceuticals Limited의 수익 기록 (2005 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $316.40M | 1.24% |
| 2025 | $312.51M | 10.79% |
| 2024 | $282.08M | 25.50% |
| 2023 | $224.77M | 39.18% |
| 2022 | $161.50M | -22.54% |
| 2021 | $208.49M | 32.37% |
| 2020 | $157.51M | 94.73% |
| 2019 | $80.88M | -43.43% |
| 2018 | $142.99M | -14.78% |
| 2017 | $167.79M | -52.57% |
| 2016 | $353.73M | 134.86% |
| 2015 | $150.61M | -3.94% |
| 2014 | $156.79M | 46.48% |
| 2013 | $107.04M | 51.35% |
| 2012 | $70.72M | -8.03% |
| 2011 | $76.89M | -0.54% |
| 2010 | $77.31M | 104.22% |
| 2009 | $37.86M | 1.60% |
| 2008 | $37.26M | 48.13% |
| 2007 | $25.15M | 44.18% |
| 2006 | $17.45M | 33.96% |
| 2005 | $13.02M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 457.70% |
IN
|
